Winning Bizness Desk
Mumbai. Starting April 1, the prices of nearly 400 essential medicines, including those used for diabetes, high blood pressure, infections, and pain relief, will rise by 1.74%. The National Pharmaceutical Pricing Authority (NPPA) has announced this routine price revision, which is carried out annually to reflect market trends. The increase is based on the Wholesale Pricing Index (WPI) for 2024, which rose by 1.74% compared to the previous year. This adjustment allows pharmaceutical manufacturers to revise the maximum retail price of scheduled drugs without prior approval from the government.
National List of Essential Medicines (NLEM)
India introduced the National List of Essential Medicines (NLEM) in 1996 to ensure the affordability and accessibility of critical drugs. The list has been revised four times, with the latest update in 2022. The current NLEM includes 384 essential medicines, with 34 new additions and 26 deletions. These drugs are categorized based on their usage in primary, secondary, or tertiary healthcare settings. The periodic revision of NLEM helps keep pace with changing disease patterns, advancements in medical treatments, and the removal of obsolete medicines. It also serves as a reference for government procurement policies to make healthcare more affordable.
Price Control Mechanism for Essential Medicines
To regulate the cost of essential medicines, the NPPA sets a ceiling price for drugs listed under the NLEM. This ceiling price is determined by averaging the retail prices of all generic and branded generics that hold at least a 1% market share, with a small margin added for retailers. This mechanism prevents excessive pricing and ensures that life-saving drugs remain accessible to the public. The price increase from April 1 follows this methodology, making it a structured and predictable adjustment rather than an arbitrary hike.
Regulation of Non-Scheduled Drugs
Apart from essential medicines, the NPPA also monitors the pricing of non-scheduled drugs, which are not included in the NLEM. However, pharmaceutical companies are restricted from raising their prices beyond 10% annually. This dual pricing system helps maintain a balance between affordability and market dynamics. By capping the price hike for both scheduled and non-scheduled drugs, the government aims to prevent undue financial burdens on patients while ensuring that pharmaceutical companies remain viable in a competitive market.
Impact on Healthcare and Availability
The price revision comes at a time when India has witnessed a significant rise in lifestyle diseases such as diabetes and heart ailments. According to the National Crime Records Bureau (NCRB), 32,457 people died from heart attacks in 2022, reflecting a 12.5% increase from the previous year. The NPPA has also set new ceiling prices for critical injections, including ringer lactate solutions and injectable combinations of piperacillin and tazobactam. These adjustments highlight the importance of balancing affordability with industry sustainability while ensuring that essential medicines remain accessible to those in need.
